The new European health technology assessment (EU-HTA) has reached an important milestone

The new European health technology assessment (EU-HTA) has reached an important milestone: the first joint assessment – led by Ireland's National Centre for Pharmacoeconomics (NCPE) as assessor and IQWiG as co-assessor - has been adopted by the Member State Coordination Group on HTA (HTACG).

The first Joint Clinical Assessment (JCA) covered the cancer drug tovorafenib, used to treat pediatric low-grade glioma.

The JCA will be published after review by the European Commission. It will then feed into Germany's national AMNOG process, where manufacturers can refer to the European dossier instead of submitting their own clinical evidence. Because tovorafenib is an orphan drug -indicated for a rare disease - the assessment in Germany will be carried out by the Federal Joint Committee (G-BA).